CUMYL-PEGACLONE (SGT-151) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug.[1][2][3][4][5][6] The gamma-carboline core structure seen in CUMYL-PEGACLONE had not previously been encountered in a designer cannabinoid, though it is similar in structure to other gamma-carboline cannabinoids disclosed by Bristol-Myers Squibb in 2001.
EFFECTS
Sgt-151 binds to the body’s opioid receptors, causing a range of effects. These include pain relief, euphoria, and sedation. In high doses, Sgt-151 can also cause respiratory depression, which can lead to death.
Reviews
There are no reviews yet.